Search

Displaying results 2211 - 2220 of 8517 in total
  1. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Paritaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Paritaprevir first came on the market as a fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak.

  2. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.

  3. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. … The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

  4. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  5. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.

  6. Drug

    Manganese gluconate

    go.drugbank.com/drugs/DB11141
    Approved

    Manganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement.

  7. Drug

    Cytarabine

    go.drugbank.com/drugs/DB00987
    ApprovedInvestigational

    It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

  8. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved

  9. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels ...

  10. Drug

    Chlorobutanol

    go.drugbank.com/drugs/DB11386
    ApprovedVet approvedWithdrawn

    As a long-term stabilizer of multi-ingredient preparations, chlorobutanol is normally used at a concentration of 0.5%. At this concentration, it also conserves its antimicrobial activity. … Due to the long terminal half-life of 37 days, the use of chlorobutanol as a sedative is limited because of the considerable accumulation which will occur following multiple dosing [A32743].